Cross-sectional biomarker comparisons in asthma monitoring using a longitudinal design: The eNose premise

Funding

AL, AHN, SJHV, ADK, RL and AS report no conflicts of interest. MIA reports a grant from the Egyptian Government PhD Scholarship, outside the submitted work. RdV reports personal fees from Breathomix BV, outside the submitted work. UF reports grants from Swiss National Science Foundation, during the conduct of the study. PJS reports grants from being scientific advisor and having a formally inconsiderable interest in the start‐up company Breathomix BV, during the conduct of the study. AHM reports grants from Boehringer Ingelheim and GSK, personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, outside the submitted work. The salary of AS was sponsored from the European Respiratory Society‐Marie Sklodowska Curie actions COFUND RESPIRE 2 fellowships (MCF‐7077–2014), from a grant supported by Lungenliga, Swiss Lung Foundation (2017_14) and internal funds. The salary of MIA was sponsored by the Egyptian Government PhD Research Scholarships. The work was supported by an unrestricted grant from Chiesi Pharmaceuticals, institutional funding from the Amsterdam University Medical Centre, Amsterdam UMC, University of Amsterdam (IA601011). The salary of AS was sponsored from the European Respiratory Society-Marie Sklodowska Curie actions COFUND RESPIRE 2 fellowships (MCF-7077–2014), from a grant supported by Lungenliga, Swiss Lung Foundation (2017_14) and internal funds. The salary of MIA was sponsored by the Egyptian Government PhD Research Scholarships. The work was supported by an unrestricted grant from Chiesi Pharmaceuticals, institutional funding from the Amsterdam University Medical Centre, Amsterdam UMC, University of Amsterdam (IA601011).